Secukinumab at the EULAR 2013 Meeting

I’ve already written on secukinumab: http://rheumatologe.blogspot.de/2013/06/targeting-interleukin-17-in-patients.html. Here’s more on this drug.

X. Baraliakos and colleagues presented [FRI0420]: “Long term inhibition of IL-17a with secukinumab reduces spinal inflammation but has no influence on fatty lesions as assessed by magnetic resonance imaging in patients with ankylosing spondylitis.” Quo usque tandem abutere, Catilina, patientia nostra? No, that’s a bit too hard, but it’s the same study as presented in Washington.

O.K. We’ve still got another study. U. Klein and colleagues presented [SAT0142]: “Immunogenicity of the novel anti-IL-17a antibody, secukinumab, with intravenous and subcutaneous dosing regimens in healthy subjects and patients.” Conclusions: “Based on the available data, secukinumab appears to carry a low risk of immunogenicity. In the very few transient immunogenicity positive patients identified so far, there has been no indication of altered pharmacokinetics or loss of efficacy, and no adverse event that could be linked to immunogenicity has been detected. More data from the ongoing phase 3 studies are required to strengthen this encouraging finding in a larger patient population.”

The more I read on secukinumab the surer I get. We won’t here much on RA and secukinumab.